Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial - Barron's

1. Kymera's KT-621 trial data show promise for dermatitis and asthma. 2. Stock jumped 50%, prompting multiple analysts to upgrade their ratings. 3. Analysts predict annual sales of $1.3-$2.3 billion from KT-621 by 2035. 4. The drug exhibits a clean safety profile compared to placebo. 5. Potential partnership opportunity with Regeneron due to Dupixent's revenue gap.